Fact CheckerSign in

NCT06973902Recruiting

The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF

Advanced Heart Failure: The Predictive Value of Dobutamine Echo-stress in the Clinical Response to Cardiac Contractility Modulation Therapy (CCM)

Source: ClinicalTrials.gov · Last updated 29 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this observational cohort study, which is both retrospective and prospective, is to evaluate the long-term clinical and instrumental response to Cardiac Contractility Modulation (CCM) treatment in adult subjects suffering from symptomatic heart failure (HF) due to systolic left ventricular dysfunction, despite adequate medical therapy. Based on the response to stress echocardiography with preimplantation low-dose Dobutamine, the main questions it aims to answer are: * What is the proportion of subjects who experience a clinical response to CCM therapy at 12 months (NYHA reduction ≥ 1 class)? * There was a reduction in the number of hospitalizations, visits to the Emergency Department, and access to day hospital facilities for more than 4 hours compared to the year before the study (e.g., by intravenous infusion of cardiac inotropic drugs)? * What is the estimated change in the quality-of-life score using the "Quality of Life Questionnaire with Heart Failure - Minnesota" (MLHFQ) between baseline and the end of follow-up? * What is the change in walking distance between baseline and the end of the follow-up in the walk test (6MWT) (optional)? * What is the difference in NT-proBNP levels between baseline and the end of follow-up? Participants are already receiving CCM support as part of their regular medical care for heart failure.

Status (registry)
Recruiting
Study type
Observational
Enrollment
120 (estimated)
First submitted
7 May 2025
Start date
10 Jul 2025
Primary completion date
31 Dec 2028
Lead sponsor
Quovadis Associazione
NCT number
NCT06973902

What you commit to

  • Study type: Observational
  • Planned participants: 120
  • From 10 Jul 2025 to the primary completion date, 31 Dec 2028
  • 13 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Life expectancy \< 1 year due to non-cardiac comorbidities that reduce prognosis,
  • Contraindications to the performance of the echocardiographic test under pharmacological stress (heart failure in progress, myocardial infarction in the acute phase, acute inflammatory processes of the heart muscle and/or pericardium, critical aortic valve stenosis and severe obstructions to left ventricular outflow, dissecting aneurysm of the aorta, severe arrhythmias not controlled by therapy, known hypersensitivity to the drug, intraventricular thrombi).

Other

  • Presence of contraindications to the CCM implantation procedure (absence of vascular access usable for CCM implantation, active infectious processes, active severe coagulopathies, presence of mechanical tricuspid valve),

Who the study is looking for

  • Subject of both sexes with age ≥ 18 years,
  • Ability to understand and sign informed consent to participate in the study and consent to process sensitive personal data.
  • Carrier of symptomatic heart failure, despite optimal medical therapy (OMT),
  • Reduced left ventricular systolic function (E.F. \<50%),
  • It was positively evaluated for implanting a system for cardiac contractility modulation (CCM) (according to the European Society of Cardiology 2021 Guidelines on heart failure and the provisions of the C.E. mark approval)13.
  • Have presented at least one hospitalization, access to the Emergency Department, or access to day hospital facilities for more than 4 hours (e.g., by intravenous infusion of cardiac inotropic drugs) in the year before implantation

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (13)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
OSPEDALE CASTELLI, UO Cardiologia
Coordinator of this site? Confirm its status
AnzioItalyRecruiting
Osp. Generale Provinciale Mazzoni, UO Cardiologia
Coordinator of this site? Confirm its status
Ascoli PicenoItalyActive, not recruiting
UOC Cardiologia con UTIC, Osp. Di Venere
Coordinator of this site? Confirm its status
BariItalyRecruiting
Policlinico S.Orsola, UO Cardiologia
Coordinator of this site? Confirm its status
BolognaItalyRecruiting
Fondazione Giglio, Cefalù (PA), UOC Cardiologia
Coordinator of this site? Confirm its status
CefalùItalyRecruiting
PO Anastasia Guerriero, Marcianise (CE), UOC Cardiologia
Coordinator of this site? Confirm its status
MarcianiseItalyRecruiting
Clinica Montevergine, Mercogliano (AV), Laboratorio di Elettrofisiologia
Coordinator of this site? Confirm its status
MercoglianoItalyRecruiting
Elettrofisiologia e Aritmologia, ASST FBF Sacco
Coordinator of this site? Confirm its status
MilanItalyRecruiting
UOC Cardiologia, Osp. Di Mirano, ULSS 3 Serenissima
Coordinator of this site? Confirm its status
MiranoItalyRecruiting
UOC Cardiologia, Osp. Di Piove di Sacco (PD), ULSS 6 Euganea
Coordinator of this site? Confirm its status
Piove di SaccoItalyRecruiting
UO Cardiologia, S. Maria della Misericordia Hospital, ULSS5 Polesana
Coordinator of this site? Confirm its status
RovigoItalyRecruiting
UOC Cardiologia, Osp. San Rocco, Sessa Aurunca (CE), ASL Caserta
Coordinator of this site? Confirm its status
Sessa AuruncaItalyRecruiting
UOC Cardiologia, Osp. S.Bortolo, Vicenza, ULSS 8 Berica
Coordinator of this site? Confirm its status
VicenzaItalyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.